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Basophils have been implicated as a source of histamine and 
pro-inflammatory eicosanoids in atopic dermatitis. How-
ever, mechanisms regulating basophil mediator release are 
not understood. An H3 receptor involved in the control of 
histamine synthesis and release has been identified in nervous 
tissue. In this study we have investigated 1) release of hista-
mine, leukotriene C4 , and prostaglandin D2 from anti-
immunoglobulin E (lgE) - stimulated basophils of adults 
with atopic dermatitis and unaffected individuals and 2) spe-
cific H3 receptor - dependent basophil mediator release, 
using an H3 receptor agonist and antagonist. 
Basophil-rich leukocyte fractions were prepared by dex-
tran sedimentation of venous blood from 19 patients with 
atopic dermatitis (five male, 14 female, mean age 30.6 years, 
range 19 - 59 years) and 15 unaffected individuals (five male, 
10 female, mean age 27.6 years, range 19-50 years). Anti-
IgE (0.78- 78.0 flg/ml) stimulation Q..f basophils induced a 
concentration-dependent release of histamine and leuko-
triene C4 , but notjrostaglandin D2 • Histamine release was 
maximally induce by 7.8 flg/ml anti-IgE with no signifi-
cant (Mann-Whitney U test) difference between atopic ba-
sophils (n = 17; 43.65 ± 4.16% mean ± SEM) and normal 
A topic dermatitis (AD) is a common pruritic skin dis-order that often begins in early infancy and frequently occurs in patients with a personal or family history of atopic disease. Although the etiology of AD has not yet been established, histamine has been implicated as 
a mediator in the chronic itch and erythema associated with AD. 
There is evidence to indicate that basophils from children with AD 
are hyper-reactive and release more histamine than basophils from 
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Abbreviations: 
AD: atopic dermatitis 
c-AMP: adenosine 3'5' -cyclic monophosphate 
ETYA: eicosa-5,8,1l,14-tetraynoic acid 
Ig: immunoglobulin 
LPR, late-phase reaction 
L TC4: leukotriene C4 
PC: prostaglanrlin 
(R)a-MeHA: (R)a-methylhistamine 
RIA: radioimmunoassay 
basophils (n = 13; 52.23 ± 4.39%). LTC4 release was maxi-
mal from atopic basophils incubated with 2.6 flg/ml anti-IgE 
(n = 5; 0.99 ± 0.29 pg/106 cells) and from normal basophils 
incubated with 0.78 flg/ml anti-IgE (n = 5; 25.38 ± 5.79 
pg/106 cells) . Anti-IgE-stimulated release ofleukotriene C4 
from atopic basophils was significantly less than from normal 
basophils at all concentrations (p < 0.05). 
Basophils were co-incubated with anti-IgE (2.6 and 7.8 
flg/~ll) and either the H3 receptor agonist, (R)a-methylhis-
tat?me (1~-8 and 10- 7 M), or the H3 receptor antagonist 
thl<?peram.lde (10- 6 and 10-5 M). Neither drug modulated 
antl-IgE-mduced release of histamine (atopies, n = 10; nor-
mals, n = 8). 
These resul ts indicate 1) that basophils from adults with 
atopic dermatitis release the same amount of histamine as, but 
less leukotriene C4 than, basophils of unaffected adults and 2) 
that H3 receptors are not involved in anti-IgE release ofhista-
mine from basophils. These data do not support a role for 
increased basophil release of histamine as a mediator in the 
itch and erythema of atopic dermatitis in adults.] Inllest Der-
matoi100:305 -309, 1993 
unaffected individuals [1) . However, in adults the evidence is less 
conclusive (2). 
A?tigen stimulation of.baso~hils ill vitro induces release of only a 
P?rtJo~ of the avatlable 11lStaml11e [1,2) and mechanisms regulating 
hlstaml11e release are not well understood. Arachidonic acid and 
indomethacin have been shown to enhance histamine release 
whereas the dual cyclooxygenasejlipoxygenase inhibitor eicosa-
5,8,11,14-tetraynoic acid (ETYA) inhibits release, indicating that 
lipoxygenase products may be involved (3). Agents that increase 
intracellular adenosine 3'5' -cyclic monophosphate (c-AMP) levels 
also ~lock .release (4), as does histamine itself (5). In contrast, H2 
al:t1hls~aml11es (H2 receptor antagonists) increase antigen-induced 
hlstam~ne release, reportedly by blocking the capacity of released 
hlstaml11e t~ act on .H2 receptors and inhibit further release [5]. In 
more extensive studies, Arrang and colleagues (6) demonstrated that 
t~e ability of histamine to inhibit its own release from depolarized 
shces of rat cerebral cortex was not mimicked by several histaminer-
gic agents. Furthermore, they demonstrated that both the H2 recep-
tor agonist, impromidine and partial antagonist burimamide atten-
uated the ability of exogenous histamine to block its own release. 
This effect was observed at concentrations at least 100 times lower 
than those re9uired to elicit the post synaptic H2 receptor response, 
I.e., modulatIOn of c-AMP formation. Arrang and colleagues con-
cluded that histamine inhibition of its own release is mediated by a 
class of receptors (H3) pharmacologically distinct from the classical 
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HI or H2 receptors. The development of selective ligands for H3 
receptors in brain [7] now makes it possible to investigate the exis-
tence of these receptors on other cells that synthesize and release 
histamine, such as basophils. They also makes it possible to deter-
mine if altered auto-regulation of histamine release is associated 
with inflammatory disorders in which histamine has been impli-
cated, such as AD. 
Exposure to appropriate antigen induces a biphasic cutaneous 
response in allergic individuals [8]. The immediate hypersensitivity 
reaction, characterized by increased cutaneous levels of histamine, 
leukotriene C4 (LTC4), and prostaglandin D2 (PGD2), is thought to 
be mediated primarily by skin mast cells that release histamine and 
PGD2 [9,10]' whereas LTC4 is thought to originate from infiltrat-
ing eosinophils [9]. The cellular source of mediators involved in the 
late-phase reaction (LPR) is much less clear. However, in skin the 
LPR is characterized by a basophilic infiltrate and secondary in-
crease in cutaneous histamine but not prostaglandin D2 levels [11]. 
Basophils release L TC4 as their major arachidonic acid metabolite 
and not PGD2 [12,13], and therefore it has been concluded that the 
basophil is the predominant source of mediators of the cutaneous 
LPR [11]. The role of the basophil in AD is unclear; however, its 
putative involvement in LPR suggests that it may play a role in 
chronic inflammatory dermatoses. 
The aim of the present study has been to investigate basophil 
function in normal and atopic individuals. We have investigated 
release of histamine, L TC4, and PGD2 from basophils and the abil-
ity of H3 receptor ligands to modulate release. 
MATERIALS AND METHODS 
Materials The histamine H3 receptor agonist (R)a-methyl hista-
mine [(R)a-MeHA) and the H3 receptor antagonist thioperamide 
[MR 12842, N -cyclohexyl-4-(imidazol-4-yl)-1-piperidinecarboth-
ioamide] were generous gifts from Prof. Schwartz and Dr. Arrang, 
Centre Paul Broca de I'INSERM, Paris, France. 
Polyclonal rabbit anti-human IgE (IgE / FCE fragment) was ob-
tained from Dako, High Wycombe, Buckinghamshire, UK. LTC4 
and PGD2 radioimmunoassay kits were obtained from Amersham 
pic, UK. 
Patients Nineteen adults with clinically demonstrable AD (five 
male, 14 female, mean age 30.6 years, range 19-59 years) and 15 
unaffected individuals with no family history of atopic disease (five 
male, 10 female, mean age 27.6 years, range 19-50 years) were 
recruited for this study. The patients had a history of AD since early 
infancy and when recruited for this study their disease was active but 
stable over the previous year on the same treatment. Donors re-
ceived no systemic or topical medication other than emollients for 2 
weeks prior to blood being collected for this study. All the patients 
and controls used in this study had normal white blood cell counts. 
Preparation of Basophil-Rich Leukocyte Suspension Blood 
was collected by venepuncture into heparinized vacutainers and the 
basophil-rich leukocyte fraction isolated by dextran sedimentation 
[14]. Briefly, 40 ml of venous blood was mixed with 10 ml Dextran 
T70 containing 300 mg glucose and 1 ml heparin (5000 U /ml) and 
allowed to sediment at room temperature for 1 h. The leukocyte 
fraction was aspirated and the cells pelleted by centrifugation 
(1500 X g, 5 min at room temperature). The pellet was resuspended 
in Tyrode's buffer (8 g/I NaCl, 1 g/I glucose, 2.86 g/I Hepes, 0.2 
g/I KCI, 0.147 g/I CaCI2, 0.063 g/I NaH2P04, pH 7.4) and the 
cells washed three times and finally resuspended in Tyrode's buffer 
at 37"C. The final volume was equivalent to 1/10 of original vol-
ume of venous blood sample and the total white cell count was less 
than 5 X 106/ml. 
Antigen-Induced Mediator Release Anti - immunoglobulin E 
(IgE) (0.78-78 Jig/ml) was added to a 1-ml aliquot of pre-warmed 
cell suspension and incubated at 37°C for 30 min with agitation 
every 5 min. At the end of the incubation period, 0.5 ml cold Tyr-
ode's buffer was added to each tube to terminate the reaction. The 
tubes were then centrifuged (1500 X g, 3 min) and the supernatant 
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decanted. The pellet was resuspended in 1 ml of Tyro de's buffer and 
the cells lysed by the addition of 35111 perchloric acid (72% w /w). 
Total cellular content and spontaneous release of histamine, L TC4, 
and PGD2 were assessed in cells incubated in the absence of anti-
IgE. 
H3 Receptor Experiments The H3 receptor agonist (R)a-
MeHA and antagonist thioperamide were used to determine 
whether there were any effects of binding at this receptor on hista-
mine release. The concentration of ligands used in these experi-
ments were in the range shown to be efficacious by Arrang et al in 
their original exr.eriments [7]. (R)a-MeHA inhibition of K+-in-
duced release of l3H]-histamine in slices of rat cerebral cortex was 
concentration dependent with ECso of 4 X 10- 9 M and maximal 
inhibition with 10- 7 M. The inhibitory action of 10- 7 M (R)a-
MeHA was completely blocked by 10- 6 M thioperamide. 
In the present experiments, the cell suspension was incubated 
with anti-IgE (2.6-7.8 Ilg/ml) and either (R)a-MeHA (10- 8 -
10- 7 M) or thioperamide (10- 6 - 10- s M) for 30 min at 37° C, after 
which time the cells were processed for histamine and eicosanoid 
assays. 
Histamine Measurement Histamine in the cell supernatant and 
lysed cell pellet was measured by automated fluorometric assay 
using an Auto-Technicon analyzer calibrated with known concen-
trations of histamine [14,15]. The total histamine content in each 
reaction tube is calculated from the histamine content of the cell 
supernatant and lysed cell pellet. 
Histamine release is given as the amount of amine found in the 
supernatant expressed as a percentage of the total amine in the cells 
and supernatant and is corrected, unless otherwise stated, for sponta-
neous release in the absence of anti-IgE. The samples were assayed 
in duplicate. 
Release of histamine in the presence of (R)a-MeHA and thioper-
amide was compared with spontaneous histamine release in the 
absence of anti-IgE to exclude any effect of these compounds in the 
histamine assay. 
Eicosanoid Assays L TC4 and PG O2 were measured using radio-
immunoassay kits. Briefly, each assay tube contained 50111 of sam-
ple, 1500 cpm [3H]-LTC4, or [3H]-PGD2 in 50 111 assay buffer (Tyr-
odes buffer containing 35111 perchloric acid, pH 5.5) and 50 Jil of 
specific antiserum. The L TC4 antiserum exhibited 5% cross-reacti-
vity with LTD4 and 0.5% with L TE4, whereas the PGD2 antiserum 
exhibited 7% cross-reactivity with PGJ2 and less than 0.5% cross-
reactivity with thromboxane B2 and other prostaglandins of the 
2-series. Standard curves covered the ranges 8 pg up to 500 pg of 
L TC4 and 3 pg up to 200 pg PG O2. The assay tubes were incubated 
overnight at 4°C and the bound tritiated LTC4 or PGD2 was sepa-
rated from unbound by dextran charcoal precipitation. Two-
hundred microliters of supernatant was counted in 2 ml of Ecoscint 
scintillation fluid (National Diagnostics). Each sample was assayed 
in duplicate without prior extraction and the results are expressed as 
pg/l06 cells. The number of basophils in each reaction tube was 
calculated from the amount of histamine, assuming that each baso-
phil contains 1 pg histamine/basophil as previously described [12]. 
Analysis of Data Statistical comparison of release of histamine 
and eicosanoids from the basophils of patients with AD and unaf-
fected individuals was performed using the Mann-Whitney U test 
and results were considered to be significant if p < 0.05. The effects 
of the H3 receptor agonist and antagonist were analyzed using the 
Student t test for paired data. p < 0.05 was considered to be statisti-
cally significant. 
RESULTS 
Anti-IgE-Induced Release of Histamine Two of 19 atopic 
patients and two of 15 unaffected individuals did not release hista-
mine in response to anti-IgE and were excluded from further calcu-
lations. Spontaneous release of histamine from the unstimulated 
basophils of unaffected individuals was 5.75 ± 1.44% (mean ± 
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Figure 1. Anti-IgE-induced release of histamine from the basophils of 
patients with atopic dermatitis (II) and unaffected individuals (0). Results 
are expressed as mean ± SEM. n = 17 atopic patients, n = 15 unaffected 
individuals. 
SEM) compared to 8.94 ± 1.25% from the basophils of atopic pa-
tients; however, this difference was not statistically significant. 
Anti-IgE (0.78-78 ,ug/ml) induced a concentration-dependent re-
lease of histamine from the basophils of both unaffected and atopic 
individuals (Fig 1). The dose-response curve was bell shaped and 
maximal release of histamine in both groups was obtained with 7.8 
,ug/ml anti-IgE. 
The basophils from patients with AD released slightly less of the 
available histamine than basophils from unaffected individuals in 
response to all concentrations of anti-IgE but this difference was not 
statistically significant at any concentration of anti-IgE. 
It has been suggested that the maximum histamine release from 
normal basophils following antigen stimulation correlates with the 
age of the donor [16]; however, in this study the maximum percent-
age histamine release did not correlate with the age or sex of the 
individual in either the atopic or normal groups (R2 = 0.004, pa-
tients; R2 = 0.019, controls) (Fig 2). 
Figure 2. Effect of donor age on histamine release from atopic (e) and 
normal basophils (0) induced by 7.8 Ilg/ml anti-IgE. 
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Figure 3. Anti-IgE-induced release of LTC. from basophils of patients 
with atopic dermatitis (II) and unaffected individuals (m). Results are 
expressed as mean ± SEM, n = 5 .• p < 0.05 . 
Anti-IgE-Induced Release of LTC. and PGD2 Anti-IgE 
(0.78-78.0 ,ug/ml) stimulation ofbasophils also induced a concen-
tration-dependent release of LTC. (Fig 3). LTC. release was maxi-
mal from AD basophils incubated with 2.6 ,ug/ml anti-IgE and from 
normal basophils incubated with 0.78 ,ug/ml anti-IgE. LTC. release 
from AD basophils was significantly less than that from normal 
basophils following incubation with all concentrations of anti-IgE 
(p < 0.05). This was not due to increased retention of LTC. by AD 
basophils as the lysed pellets contained 0.20 ± 0.07 pg/106 cells 
LTC. compared to 0.62 ± 0.24 pg/1 06 cells in normal basophils. 
PG~2 was not ?etectabl.e in the supernatant or lysed cell pellet of 
basophlls from either patients With AD or unaffected individuals 
(data not shown). 
Effect of the H3 Receptor Ligands on Histamine and Eico-
sanoid Release Neither (R)a-MeHA nor thioperamide alone in-
duced release of histamine from basophils. Furthermore they did 
not modulate anti-IgE- induced histamine release in either the nor-
mal or atopic groups (Fig 4). Similarly, neither compound a10ne 
induced release of LTC. or modulated anti-IgE-induced release of 
this leukotriene (n = 2, data not shown). 
DISCUSSION 
Hista~ine, released primarily from mast cells, has been implicated 
as an Important mediator in immediate allergic inflammatory reac-
tions. However, its role in chronic inflammatory dermatoses such as 
AD is much less clear. Increased spontaneous and anti-IgE- induced 
basophil histamine release has been reported in children with AD 
[1] . The results of our study indicate that this is not the case in adu lts 
with AD. There is no significant difference in either the spontane-
ous or anti-IgE- induced histamine release from basophils of adults 
with AD and unaffected individuals. Moreover, we found no corre-
lation in either group between the age or sex of these adult donors 
and the amount of histamine released. The results of this study do 
not support a role for excessive release of histamine from basophils 
as a mechanism in the itch and erythema in AD. They do not, 
however, preclude altered release kinetics. Histamine has been dem-
onstrated to regulate its own release from basophils and this was 
thought to be mediated via H2 receptor occupancy [5]. Specific 
histamine H3 receptors involved in the regulation of histamine syn-
thesis and release in nervous tissue have been identified and ligands 
developed that modulate the action of histamine through this re-
ceptor. Using the specific H 3 agonist and antagonist, we have been 
unable to demonstrate altered spontaneous or anti-IgE-stimulated 
release of histamine from the basophils of either atopic or normal 
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Figure 4. Effect of lhe H3 receptor agonist (R)aMeHA (ll1lI) and the H3 
receptor antagonist thioperamide (II1II) on basophil histamine release in-
duced by 2.6 J.lg/ml or 7.8 J.lg/ml anti-IgE. 0 , histamine release induced 
by anti-igE alone. Results are expressed as mean + SEM. n = 10 atopic 
patients, n = 8 unaffected individuals. 
individuals, indicating that the existence of these receptors on baso-
phils is unlikely. These findings are in agreement with those of 
Kleine-Tebbe et al whose work, utilizing the H3 antagonist thioper-
amide, provided no evidence for H3 receptors on normal basophils 
[17]. 
As well as being a source of histamine , basophils also release LTC4 
as their major arachidonic acid conversion product. Intradermal 
injection of L TC4 into human skin induces an immediate erythema 
and wealing [18,19], indicating that L TC4 may be a potential media-
tor of vasodilatation and increased vascular permeability in inflam-
matory dermatoses such as AD [16]. We have found that, fo llowing 
stimulation with anti-IgE, basophils from patients with AD release 
significantly less L TC4 than basophils from unaffected individuals. 
This is not the result of increased retention ofLTC4 by the basophils 
of atopic individuals as the content of the lysed cell pellet was 
similar in both groups. Nor is it due to increased catabolism of 
LTC4. Significant catabolism ofLTC4 to LTE4 has been reported to 
occur in vitro over a 45-min incubation period only when the total 
white cell count in the mixed leukocyte preparation is greater than 
5 X 106/ml [12]. In the present study the total white cell count in 
the mixed leukocyte preparations from both atopic patients and 
control subjects was less than 5 X 106/mL 
Conversion of arachidonic acid to eicosanoids is subject to strict 
regulation and synthesis of a cell specific eicosanoid is often fol-
lowed by a period when the cells are refractory to further stimula-
tion. The reduced release of L TC4 from the basophils of atopic 
individuals may be indicative of prior in vivo activation by chronic 
submaximal stimulation that has rendered the cells refractory to 
stimulation with the concentrations of anti-IgE used in these exper-
iments. In similar studies Schafer et al [20] have reported that neu-
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trophils from adult patients with AD release less L TB4 than neutro-
phils from control subjects and they concluded that the defect was 
due to a reduction in the capacity of atopic neutrophils to convert 
arachidonic acid into leukotrienes . 
The lack of PGD2 in the supernatant of basophils from either 
normal or atopic individuals confirms previous results that failed to 
detect PGD2 release from basophils in vitro [12] or with the influx of 
basophils associated with cutaneous LPR [11]. 
Histamine is synthesized and stored in basophils and mast cells 
and is secreted from storage granules following appropriate stimula-
tion. In contrast, eicosanoids including L TC4 are synthesized de novo 
upon receipt of appropriate signals. There is already evidence that 
the amount of histamine released from basophils ill vitro is depen-
dent on the stimulus used [16] and there is increasing evidence that 
extent of L TC4 synthesis and release is also agonist dependent [21]; 
basophils from "allergic" and normal individuals incubated with 
the potent chemoattractant platelet-activating factor (PAF) synthe-
size and release substantially more L TC4 than do basophils from the 
same patients incubated with anti-IgE. Furthermore, the ratio of 
L TC4 release to histamine release is much greater after stimulation 
with P AF than with anti-IgE [22] . 
The results of our experiments indicate that chronic submaximal 
stimulation of basophils from patients with AD in vivo may have 
preferentially induced synthesis and release of L TC4 such that the 
concentrations of anti-IgE used in our experiments in vitro were 
insufficient to induce further synthesis and release ofL TC4 but were 
sufficient to induce release of histamine. Furthermore, these results 
indicate that assessment of histamine release alone may not be an 
appropriate indicator of basophil function/dysfunction in AD. Ad-
ditional assessment of synthesis and release of other mediators and 
pathways of activation may provide a more accurate picture ofbaso-
phil function. 
In conclusion, results of experiments presented here indicate that 
basophils from adults with AD release the same amount of hista-
mine as, but less L TC4 than, basophils of unaffected adults. In addi-
tion they demonstrate that H3 receptors are not involved in anti-IgE 
release of histamine from either normal or AD basophils. These data 
do not support a role for increased basophil release of histamine as a 
mediator in the itch and erythema of AD in adults. 
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MEETING ANNOUNCEMENT 
Workshop on the Epidemiology of Skin Diseases 
March 25 and March 26, 1993 
National Institutes of Health 
Building 31, Conference Room 10 
9000 Rockville Pike 
Bethesda, Maryland 
Objectives: 
• To present attendants with a current overview of the present status of epidemiological 
research into skin diseases, including but not limited to: 
Chronic cutaneous ulcers 
Dermatologic aspects of HIV infection 
Ichthyosis 
Non-melanoma skin cancer 
Psoriasis 
Toxic epidermal necrolysis 
• To identify areas in which epidemiological studies could advance the understanding, manage-
ment, and prevention of skin diseases . 
• To encourage more research into the epidemiology of skin diseases. 
Potential participarlts: 
Dermatologists and epidemiologists with an interest in skin diseases. 
Plannirlg Committee: 
Robert S. Stern, M.D., Harvard Medical School, Boston, Massachusetts 
Martin A. Weinstock, M.D., Ph.D., VA Medical Center, Providence, Rhode Island 
David W. Kaufman, Sc.D., Boston University School of Medicine, Massachusetts 
Kayvon H. Safavi, M.D., M.P.H ., St. Luke's Medical Center, Milwaukee, Wisconsin 
Alan Moshell, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases, 
Bethesda, Maryland 
Reva C. Lawrence, M.P.H ., National Institute of Arthritis and Musculoskeletal and Skin 
Diseases, Bethesda, Maryland 
Sponsor: 
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 
Information and Pre-registration: 
Call Suzanne Sangalan at (301) 496-0803. 
